Abstract
Peripheral arterial disease (PAD) is a common disorder usually associated with silent or symptomatic arterial disease elsewhere in the circulation and a “cluster†of cardiovascular risk factors (e.g. smoking, dyslipidemia, hypertension, and insulin resistance/ diabetes mellitus). The medical management of PAD should focus on both the relief of symptoms and prevention of secondary cardiovascular complications. This approach must include smoking cessation, optimal cholesterol levels, blood pressure and glycemic control as well as prescribing antiplatelet therapy. This review focuses on the evidence supporting the use of lipid-lowering drugs in PAD. Several trials indicate that getting low density lipoprotein-cholesterol levels to target ( < 2.6 mmol/l; 100 mg/dl), or even lower, is associated with improvement of symptoms and a reduction in vascular events in patients with PAD.
Keywords: Peripheral arterial disease, risk factors, dyslipidemia, lipid lowering, statins, prevention
Current Drug Targets
Title: Lipid Management and Peripheral Arterial Disease
Volume: 8 Issue: 4
Author(s): S. S. Daskalopoulou, M. E. Daskalopoulos, D. P. Mikhailidis and C. D. Liapis
Affiliation:
Keywords: Peripheral arterial disease, risk factors, dyslipidemia, lipid lowering, statins, prevention
Abstract: Peripheral arterial disease (PAD) is a common disorder usually associated with silent or symptomatic arterial disease elsewhere in the circulation and a “cluster†of cardiovascular risk factors (e.g. smoking, dyslipidemia, hypertension, and insulin resistance/ diabetes mellitus). The medical management of PAD should focus on both the relief of symptoms and prevention of secondary cardiovascular complications. This approach must include smoking cessation, optimal cholesterol levels, blood pressure and glycemic control as well as prescribing antiplatelet therapy. This review focuses on the evidence supporting the use of lipid-lowering drugs in PAD. Several trials indicate that getting low density lipoprotein-cholesterol levels to target ( < 2.6 mmol/l; 100 mg/dl), or even lower, is associated with improvement of symptoms and a reduction in vascular events in patients with PAD.
Export Options
About this article
Cite this article as:
Daskalopoulou S. S., Daskalopoulos E. M., Mikhailidis P. D. and Liapis D. C., Lipid Management and Peripheral Arterial Disease, Current Drug Targets 2007; 8 (4) . https://dx.doi.org/10.2174/138945007780362737
DOI https://dx.doi.org/10.2174/138945007780362737 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Exercise Rehabilitation for the Patient with Intermittent Claudication: A highly Effective yet Underutilized Treatment
Current Drug Targets - Cardiovascular & Hematological Disorders Novel Anti-Platelets in Stable Coronary Artery Disease
Current Pharmaceutical Design The Oxygen Therapy
Current Medicinal Chemistry Lipoprotein Subfractions, Uric Acid and Cardiovascular Risk in End-Stage Renal Disease (ESRD) Patients
Current Vascular Pharmacology Preface
Current Topics in Medicinal Chemistry Arylpiperazines with Affinity Toward a1-Adrenergic Receptors
Current Medicinal Chemistry Fighting Type-2 Diabetes: Present and Future Perspectives
Current Medicinal Chemistry Complement Activation-Related Pseudoallergy Caused by Amphiphilic Drug Carriers: The Role of Lipoproteins
Current Drug Delivery The Adult Patient with Eisenmenger Syndrome: A Medical Update after Dana Point Part III: Specific Management and Surgical Aspects
Current Cardiology Reviews Knowledge and Perceptions Towards Cardiovascular Disease Prevention Among Patients with Type 2 Diabetes Mellitus: A Review of Current Assessments and Recommendations
Current Diabetes Reviews Amniotic Fluid Embolism: Moving Diagnosis Through the Time. From the Mechanical Pulmonary Vascular Occlusion Until An Immuno - Inflammatory Pathogenesis?
Current Pharmaceutical Biotechnology Meet Our Associate Editor
Current Molecular Medicine Soluble Epoxide Hydrolase Inhibitors and their Potential for Treatment of Multiple Pathologic Conditions
Current Medicinal Chemistry Vascular effects of flavonoids
Current Medicinal Chemistry Apoptosis Modulated by Oxidative Stress and Inflammation During Obstructive Nephropathy
Inflammation & Allergy - Drug Targets (Discontinued) Phytochemical, Anti-diabetic and Cardiovascular Properties of Urtica dioica L. (Urticaceae): A Review
Mini-Reviews in Medicinal Chemistry Pharmacotherapy and Prevention of Vascular Dementia
CNS & Neurological Disorders - Drug Targets <i>Nigella sativa</i> – A Functional Spice From A Pharaoh’s Tomb to Modern Healthcare
The Natural Products Journal Improving of Nutraceutical Features of Many Important Mediterranean Vegetables by Inoculation with a New Commercial Product
Current Pharmaceutical Biotechnology Editorial [Hot topic: Crucial Role of Redox Signaling in the Regulation of Heart Health (Guest Editor: Dipak K. Das)]
Current Cardiology Reviews